{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:03:19Z","timestamp":1793120599562,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007351","name":"Secretaria de Ciencia y Tecnica, Universidad de Buenos Aires","doi-asserted-by":"publisher","award":["20020190100119BA"],"award-info":[{"award-number":["20020190100119BA"]}],"id":[{"id":"10.13039\/501100007351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11357-022-00672-7","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T10:03:48Z","timestamp":1666173828000},"page":"707-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5110-8773","authenticated-orcid":false,"given":"Jorge","family":"Quarleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"issue":"8","key":"672_CR1","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1073\/pnas.78.8.4887","volume":"78","author":"VR Racaniello","year":"1981","unstructured":"Racaniello VR, Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci U S A. 1981;78(8):4887\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4523","key":"672_CR2","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.6272391","volume":"214","author":"VR Racaniello","year":"1981","unstructured":"Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981;214(4523):916\u20139.","journal-title":"Science"},{"key":"672_CR3","first-page":"211","volume":"299","author":"VI Agol","year":"2006","unstructured":"Agol VI. Molecular mechanisms of poliovirus variation and evolution. Curr Top Microbiol Immunol. 2006;299:211\u201359.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"672_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1128\/jvi.62.2.558-562.1988","volume":"62","author":"CD Ward","year":"1988","unstructured":"Ward CD, Stokes MA, Flanegan JB. Direct measurement of the poliovirus RNA polymerase error frequency in vitro. J Virol. 1988;62(2):558\u201362.","journal-title":"J Virol"},{"issue":"18","key":"672_CR5","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1021\/bi035212y","volume":"43","author":"JJ Arnold","year":"2004","unstructured":"Arnold JJ, Cameron CE. Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg2+. Biochemistry. 2004;43(18):5126\u201337.","journal-title":"Biochemistry"},{"issue":"1\u20132","key":"672_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0168-1702(00)00256-2","volume":"74","author":"VR Wells","year":"2001","unstructured":"Wells VR, Plotch SJ, DeStefano JJ. Determination of the mutation rate of poliovirus RNA-dependent RNA polymerase. Virus Res. 2001;74(1\u20132):119\u201332.","journal-title":"Virus Res"},{"key":"672_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0065-3527(08)60519-9","volume":"34","author":"VR Racaniello","year":"1988","unstructured":"Racaniello VR. Poliovirus neurovirulence. Adv Virus Res. 1988;34:217\u201346.","journal-title":"Adv Virus Res"},{"issue":"3","key":"672_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/infdis\/151.3.420","volume":"151","author":"AB Sabin","year":"1985","unstructured":"Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 1985;151(3):420\u201336.","journal-title":"J Infect Dis"},{"issue":"34","key":"672_CR9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.15585\/mmwr.mm7034a1","volume":"70","author":"JP Bigouette","year":"2021","unstructured":"Bigouette JP, et al. Progress toward polio eradication - worldwide, January 2019-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1129\u201335.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"25","key":"672_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.15585\/mmwr.mm6925a4","volume":"69","author":"AN Chard","year":"2020","unstructured":"Chard AN, et al. Progress toward polio eradication - worldwide, January 2018-March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):784\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"19","key":"672_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.15585\/mmwr.mm7119a2","volume":"71","author":"A Rachlin","year":"2022","unstructured":"Rachlin A, et al. Progress toward polio eradication - worldwide, January 2020-April 2022. MMWR Morb Mortal Wkly Rep. 2022;71(19):650\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"672_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.15585\/mmwr.mm7115a2","volume":"71","author":"AL Wilkinson","year":"2022","unstructured":"Wilkinson AL, et al. Surveillance to track progress toward polio eradication - worldwide, 2020\u20132021. MMWR Morb Mortal Wkly Rep. 2022;71(15):538\u201344.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"672_CR13","doi-asserted-by":"publisher","first-page":"10261","DOI":"10.1074\/jbc.M307806200","volume":"279","author":"CE Malnou","year":"2004","unstructured":"Malnou CE, et al. Effects of vaccine strain mutations in domain V of the internal ribosome entry segment compared in the wild type poliovirus type 1 context. J Biol Chem. 2004;279(11):10261\u20139.","journal-title":"J Biol Chem"},{"issue":"2","key":"672_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0042-6822(85)90127-8","volume":"147","author":"YV Svitkin","year":"1985","unstructured":"Svitkin YV, Maslova SV, Agol VI. The genomes of attenuated and virulent poliovirus strains differ in their in vitro translation efficiencies. Virology. 1985;147(2):243\u201352.","journal-title":"Virology"},{"issue":"1","key":"672_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/JVI.77.1.115-122.2003","volume":"77","author":"K Ochs","year":"2003","unstructured":"Ochs K, et al. Impaired binding of standard initiation factors mediates poliovirus translation attenuation. J Virol. 2003;77(1):115\u201322.","journal-title":"J Virol"},{"issue":"40","key":"672_CR16","doi-asserted-by":"publisher","first-page":"15471","DOI":"10.1074\/jbc.RA118.004913","volume":"293","author":"BC Avanzino","year":"2018","unstructured":"Avanzino BC, et al. Molecular mechanism of poliovirus Sabin vaccine strain attenuation. J Biol Chem. 2018;293(40):15471\u201382.","journal-title":"J Biol Chem"},{"issue":"23","key":"672_CR17","doi-asserted-by":"publisher","first-page":"9197","DOI":"10.1073\/pnas.0900153106","volume":"106","author":"S de Breyne","year":"2009","unstructured":"de Breyne S, et al. Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites. Proc Natl Acad Sci U S A. 2009;106(23):9197\u2013202.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"672_CR18","doi-asserted-by":"publisher","first-page":"7642","DOI":"10.1073\/pnas.90.16.7642","volume":"90","author":"CU Hellen","year":"1993","unstructured":"Hellen CU, et al. A cytoplasmic 57-kDa protein that is required for translation of picornavirus RNA by internal ribosomal entry is identical to the nuclear pyrimidine tract-binding protein. Proc Natl Acad Sci U S A. 1993;90(16):7642\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"672_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1017\/S1355838299981414","volume":"5","author":"SL Hunt","year":"1999","unstructured":"Hunt SL, Jackson RJ. Polypyrimidine-tract binding protein (PTB) is necessary, but not sufficient, for efficient internal initiation of translation of human rhinovirus-2 RNA. RNA. 1999;5(3):344\u201359.","journal-title":"RNA"},{"issue":"7","key":"672_CR20","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1128\/jvi.67.7.3798-3807.1993","volume":"67","author":"K Meerovitch","year":"1993","unstructured":"Meerovitch K, et al. La autoantigen enhances and corrects aberrant translation of poliovirus RNA in reticulocyte lysate. J Virol. 1993;67(7):3798\u2013807.","journal-title":"J Virol"},{"issue":"8","key":"672_CR21","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1128\/jvi.71.8.6243-6246.1997","volume":"71","author":"LB Blyn","year":"1997","unstructured":"Blyn LB, et al. Requirement of poly(rC) binding protein 2 for translation of poliovirus RNA. J Virol. 1997;71(8):6243\u20136.","journal-title":"J Virol"},{"issue":"2","key":"672_CR22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1128\/jvi.68.2.941-950.1994","volume":"68","author":"CU Hellen","year":"1994","unstructured":"Hellen CU, et al. The cellular polypeptide p57 (pyrimidine tract-binding protein) binds to multiple sites in the poliovirus 5\u2019 nontranslated region. J Virol. 1994;68(2):941\u201350.","journal-title":"J Virol"},{"issue":"21","key":"672_CR23","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1038\/emboj.2010.231","volume":"29","author":"P Kafasla","year":"2010","unstructured":"Kafasla P, et al. Polypyrimidine tract-binding protein stimulates the poliovirus IRES by modulating eIF4G binding. EMBO J. 2010;29(21):3710\u201322.","journal-title":"EMBO J"},{"issue":"3","key":"672_CR24","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1128\/jvi.63.3.1338-1344.1989","volume":"63","author":"GD Westrop","year":"1989","unstructured":"Westrop GD, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol. 1989;63(3):1338\u201344.","journal-title":"J Virol"},{"issue":"3","key":"672_CR25","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1128\/jvi.63.3.1302-1309.1989","volume":"63","author":"N Kawamura","year":"1989","unstructured":"Kawamura N, et al. Determinants in the 5\u2019 noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol. 1989;63(3):1302\u20139.","journal-title":"J Virol"},{"issue":"5","key":"672_CR26","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1128\/jvi.63.5.1884-1890.1989","volume":"63","author":"EG Moss","year":"1989","unstructured":"Moss EG, O\u2019Neill RE, Racaniello VR. Mapping of attenuating sequences of an avirulent poliovirus type 2 strain. J Virol. 1989;63(5):1884\u201390.","journal-title":"J Virol"},{"issue":"20","key":"672_CR27","doi-asserted-by":"publisher","first-page":"11097","DOI":"10.1128\/JVI.78.20.11097-11107.2004","volume":"78","author":"S Guest","year":"2004","unstructured":"Guest S, et al. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J Virol. 2004;78(20):11097\u2013107.","journal-title":"J Virol"},{"issue":"12","key":"672_CR28","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/JCI200421323","volume":"113","author":"SE Kauder","year":"2004","unstructured":"Kauder SE, Racaniello VR. Poliovirus tropism and attenuation are determined after internal ribosome entry. J Clin Invest. 2004;113(12):1743\u201353.","journal-title":"J Clin Invest"},{"issue":"8","key":"672_CR29","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1128\/JVI.77.8.4827-4835.2003","volume":"77","author":"Y He","year":"2003","unstructured":"He Y, et al. Complexes of poliovirus serotypes with their common cellular receptor, CD155. J Virol. 2003;77(8):4827\u201335.","journal-title":"J Virol"},{"issue":"5","key":"672_CR30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1086\/342682","volume":"186","author":"A Iwasaki","year":"2002","unstructured":"Iwasaki A, et al. Immunofluorescence analysis of poliovirus receptor expression in Peyer\u2019s patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. J Infect Dis. 2002;186(5):585\u201392.","journal-title":"J Infect Dis"},{"key":"672_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1742-2094-9-167","volume":"9","author":"H Gonzalez","year":"2012","unstructured":"Gonzalez H, et al. Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up. J Neuroinflammation. 2012;9:167.","journal-title":"J Neuroinflammation"},{"issue":"Pt 5","key":"672_CR32","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1099\/0022-1317-83-5-1087","volume":"83","author":"S Girard","year":"2002","unstructured":"Girard S, et al. Restriction of poliovirus RNA replication in persistently infected nerve cells. J Gen Virol. 2002;83(Pt 5):1087\u201393.","journal-title":"J Gen Virol"},{"key":"672_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijid.2015.04.018","volume":"35","author":"A Baj","year":"2015","unstructured":"Baj A, et al. Post-poliomyelitis syndrome as a possible viral disease. Int J Infect Dis. 2015;35:107\u201316.","journal-title":"Int J Infect Dis"},{"issue":"Pt 3","key":"672_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1099\/vir.0.036988-0","volume":"93","author":"PD Minor","year":"2012","unstructured":"Minor PD. The polio-eradication programme and issues of the end game. J Gen Virol. 2012;93(Pt 3):457\u201374.","journal-title":"J Gen Virol"},{"issue":"1","key":"672_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41385-021-00428-0","volume":"15","author":"RI Connor","year":"2022","unstructured":"Connor RI, et al. Mucosal immunity to poliovirus. Mucosal Immunol. 2022;15(1):1\u20139.","journal-title":"Mucosal Immunol"},{"issue":"10","key":"672_CR36","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/infdis\/jit671","volume":"209","author":"PF Wright","year":"2014","unstructured":"Wright PF, et al. Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis. 2014;209(10):1628\u201334.","journal-title":"J Infect Dis"},{"issue":"5","key":"672_CR37","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.immuni.2022.04.007","volume":"55","author":"A Lockhart","year":"2022","unstructured":"Lockhart A, Mucida D, Parsa R. Immunity to enteric viruses. Immunity. 2022;55(5):800\u201318.","journal-title":"Immunity"},{"issue":"8","key":"672_CR38","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.4049\/jimmunol.162.8.5011","volume":"162","author":"TM Herremans","year":"1999","unstructured":"Herremans TM, et al. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol. 1999;162(8):5011\u20138.","journal-title":"J Immunol"},{"issue":"suppl_1","key":"672_CR39","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1093\/cid\/ciy604","volume":"67","author":"S Resik","year":"2018","unstructured":"Resik S, et al. Does simultaneous administration of bivalent (types 1 and 3) oral poliovirus vaccine and inactivated poliovirus vaccine induce mucosal cross-immunity to poliovirus type 2? Clin Infect Dis. 2018;67(suppl_1):S51\u20136.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"672_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/infdis\/jix556","volume":"217","author":"EB Brickley","year":"2018","unstructured":"Brickley EB, et al. Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine. J Infect Dis. 2018;217(3):371\u201380.","journal-title":"J Infect Dis"},{"issue":"1","key":"672_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/315684","volume":"182","author":"S Valtanen","year":"2000","unstructured":"Valtanen S, et al. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J Infect Dis. 2000;182(1):1\u20135.","journal-title":"J Infect Dis"},{"issue":"12","key":"672_CR42","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S1473-3099(16)30169-4","volume":"16","author":"PF Wright","year":"2016","unstructured":"Wright PF, et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis. 2016;16(12):1377\u201384.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"672_CR43","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S1473-3099(19)30301-9","volume":"19","author":"GR Macklin","year":"2019","unstructured":"Macklin GR, et al. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis. Lancet Infect Dis. 2019;19(10):1121\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"672_CR44","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/infdis\/jis241","volume":"205","author":"NC Grassly","year":"2012","unstructured":"Grassly NC, et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis. 2012;205(10):1554\u201361.","journal-title":"J Infect Dis"},{"issue":"4","key":"672_CR45","doi-asserted-by":"publisher","first-page":"e001613","DOI":"10.1136\/bmjgh-2019-001613","volume":"4","author":"EB Brickley","year":"2019","unstructured":"Brickley EB, et al. Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden. BMJ Glob Health. 2019;4(4):e001613.","journal-title":"BMJ Glob Health"},{"issue":"6","key":"672_CR46","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1086\/427810","volume":"191","author":"F Abbink","year":"2005","unstructured":"Abbink F, et al. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis. 2005;191(6):990\u20139.","journal-title":"J Infect Dis"},{"issue":"4","key":"672_CR47","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000368897","volume":"61","author":"S Sato","year":"2015","unstructured":"Sato S, Kiyono H, Fujihashi K. Mucosal immunosenescence in the gastrointestinal tract: a mini-review. Gerontology. 2015;61(4):336\u201342.","journal-title":"Gerontology"},{"key":"672_CR48","doi-asserted-by":"publisher","unstructured":"Larocca AMV, Bianchi FP, Bozzi A, Tafuri S, Stefanizzi P, Germinario CA. Long-term immunogenicity of inactivated and oral polio vaccines: An Italian retrospective cohort study. Vaccines (Basel). 2022;10(8):1329.\u00a0https:\/\/doi.org\/10.3390\/vaccines10081329.","DOI":"10.3390\/vaccines10081329"},{"issue":"1","key":"672_CR49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S1474-4422(03)00633-1","volume":"3","author":"X Bosch","year":"2004","unstructured":"Bosch X. Post-polio syndrome recognised by European parliament. Lancet Neurol. 2004;3(1):4.","journal-title":"Lancet Neurol"},{"issue":"1\u20132","key":"672_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2005.04.012","volume":"236","author":"P Ragonese","year":"2005","unstructured":"Ragonese P, et al. Prevalence and risk factors of post-polio syndrome in a cohort of polio survivors. J Neurol Sci. 2005;236(1\u20132):31\u20135.","journal-title":"J Neurol Sci"},{"issue":"3","key":"672_CR51","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3233\/NRE-210216","volume":"49","author":"Z Meiner","year":"2021","unstructured":"Meiner Z, et al. Risk factors for functional deterioration in a cohort with late effects of poliomyelitis: a ten-year follow-up study. NeuroRehabilitation. 2021;49(3):491\u20139.","journal-title":"NeuroRehabilitation"},{"issue":"5\u20136","key":"672_CR52","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000497483","volume":"80","author":"L Kay","year":"2018","unstructured":"Kay L, et al. Neurological symptoms in danes with a history of poliomyelitis: lifelong follow-up of late symptoms, their association with initial symptoms of polio, and presence of postpolio syndrome. Eur Neurol. 2018;80(5\u20136):295\u2013303.","journal-title":"Eur Neurol"},{"issue":"6","key":"672_CR53","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/mus.26168","volume":"58","author":"JK Lo","year":"2018","unstructured":"Lo JK, Robinson LR. Postpolio syndrome and the late effects of poliomyelitis. Part 1. pathogenesis, biomechanical considerations, diagnosis, and investigations. Muscle Nerve. 2018;58(6):751\u20139.","journal-title":"Muscle Nerve"},{"issue":"6","key":"672_CR54","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s00415-010-5875-y","volume":"258","author":"JH Kang","year":"2011","unstructured":"Kang JH, Lin HC. Comorbidity profile of poliomyelitis survivors in a Chinese population: a population-based study. J Neurol. 2011;258(6):1026\u201333.","journal-title":"J Neurol"},{"issue":"3","key":"672_CR55","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/01.EDE.0000058920.38635.D3","volume":"14","author":"NM Nielsen","year":"2003","unstructured":"Nielsen NM, et al. Long-term mortality after poliomyelitis. Epidemiology. 2003;14(3):355\u201360.","journal-title":"Epidemiology"},{"issue":"4","key":"672_CR56","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ijc.1218","volume":"92","author":"NM Nielsen","year":"2001","unstructured":"Nielsen NM, et al. Cancer risk in a cohort of polio patients. Int J Cancer. 2001;92(4):605\u20138.","journal-title":"Int J Cancer"},{"issue":"3","key":"672_CR57","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/apmr.2001.21528","volume":"82","author":"MC Lin","year":"2001","unstructured":"Lin MC, et al. Pulmonary function and spinal characteristics: their relationships in persons with idiopathic and postpoliomyelitic scoliosis. Arch Phys Med Rehabil. 2001;82(3):335\u201341.","journal-title":"Arch Phys Med Rehabil"},{"issue":"1\u20132","key":"672_CR58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jns.2014.07.012","volume":"345","author":"I Schwartz","year":"2014","unstructured":"Schwartz I, et al. The association between post-polio symptoms as measured by the index of post-polio sequelae and self-reported functional status. J Neurol Sci. 2014;345(1\u20132):87\u201391.","journal-title":"J Neurol Sci"},{"issue":"10","key":"672_CR59","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1111\/jgs.12465","volume":"61","author":"D Amtmann","year":"2013","unstructured":"Amtmann D, et al. Symptom profiles in individuals aging with post-polio syndrome. J Am Geriatr Soc. 2013;61(10):1813\u20135.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"672_CR60","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4103\/ijabmr.IJABMR_333_18","volume":"9","author":"OJ Oluwasanmi","year":"2019","unstructured":"Oluwasanmi OJ, et al. Postpolio syndrome: a review of lived experiences of patients. Int J Appl Basic Med Res. 2019;9(3):129\u201334.","journal-title":"Int J Appl Basic Med Res"},{"issue":"5","key":"672_CR61","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/ene.15261","volume":"29","author":"MJ Wendebourg","year":"2022","unstructured":"Wendebourg MJ, et al. Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome. Eur J Neurol. 2022;29(5):1435\u201345.","journal-title":"Eur J Neurol"},{"key":"672_CR62","doi-asserted-by":"crossref","unstructured":"Brogardh C, Lexell J and Hammarlund CS. The influence of walking limitations on daily life: a mixed-methods study of 14 persons with late effects of polio. Int J Environ Res Public Health, 2022;19(13).","DOI":"10.3390\/ijerph19138157"},{"key":"672_CR63","doi-asserted-by":"crossref","unstructured":"Brogardh C, Lexell J, and Hammarlund CS. Fall-related activity avoidance among persons with late effects of polio and its influence on daily life: a mixed-methods study. Int J Environ Res Public Health, 2021;18(13).","DOI":"10.3390\/ijerph18137202"},{"issue":"10","key":"672_CR64","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jama.1987.03390100073029","volume":"257","author":"BM Nkowane","year":"1987","unstructured":"Nkowane BM, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA. 1987;257(10):1335\u201340.","journal-title":"JAMA"},{"key":"672_CR65","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","volume":"59","author":"OM Kew","year":"2005","unstructured":"Kew OM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587\u2013635.","journal-title":"Annu Rev Microbiol"},{"issue":"20","key":"672_CR66","doi-asserted-by":"publisher","first-page":"7787","DOI":"10.1093\/nar\/12.20.7787","volume":"12","author":"AJ Cann","year":"1984","unstructured":"Cann AJ, et al. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 1984;12(20):7787\u201392.","journal-title":"Nucleic Acids Res"},{"issue":"6011","key":"672_CR67","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/314548a0","volume":"314","author":"DM Evans","year":"1985","unstructured":"Evans DM, et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature. 1985;314(6011):548\u201350.","journal-title":"Nature"},{"issue":"Pt 2","key":"672_CR68","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1099\/0022-1317-56-2-337","volume":"56","author":"OM Kew","year":"1981","unstructured":"Kew OM, et al. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J Gen Virol. 1981;56(Pt 2):337\u201347.","journal-title":"J Gen Virol"},{"key":"672_CR69","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12879-016-1587-y","volume":"16","author":"T Foiadelli","year":"2016","unstructured":"Foiadelli T, et al. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis. BMC Infect Dis. 2016;16:277.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"672_CR70","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1574-695X.2009.00621.x","volume":"58","author":"B Kapusinszky","year":"2010","unstructured":"Kapusinszky B, et al. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol Med Microbiol. 2010;58(2):211\u20137.","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"2","key":"672_CR71","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1086\/421703","volume":"190","author":"CV Martinez","year":"2004","unstructured":"Martinez CV, et al. Shedding of sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. J Infect Dis. 2004;190(2):409\u201316.","journal-title":"J Infect Dis"},{"issue":"10","key":"672_CR72","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.vaccine.2015.01.018","volume":"33","author":"J Guo","year":"2015","unstructured":"Guo J, et al. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33(10):1235\u201342.","journal-title":"Vaccine"},{"issue":"49","key":"672_CR73","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.15585\/mmwr.mm7049a1","volume":"70","author":"MM Alleman","year":"2021","unstructured":"Alleman MM, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, January 2020-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(49):1691\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"672_CR74","doi-asserted-by":"publisher","first-page":"489","DOI":"10.15585\/mmwr.mm6916a1","volume":"69","author":"MM Alleman","year":"2020","unstructured":"Alleman MM, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, July 2019-February 2020. MMWR Morb Mortal Wkly Rep. 2020;69(16):489\u201395.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"45","key":"672_CR75","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.15585\/mmwr.mm6845a4","volume":"68","author":"J Jorba","year":"2019","unstructured":"Jorba J, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, January 2018-June 2019. MMWR Morb Mortal Wkly Rep. 2019;68(45):1024\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"672_CR76","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1586\/14760584.2016.1140041","volume":"15","author":"J Garon","year":"2016","unstructured":"Garon J, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693\u2013708.","journal-title":"Expert Rev Vaccines"},{"key":"672_CR77","doi-asserted-by":"publisher","unstructured":"Voorman A, Lyons H, Bennette C, Kovacs S, Makam JK, F Vertefeuille J, Tallis G. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2022:S0264-410X(22)00277-8.\u00a0https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.013.","DOI":"10.1016\/j.vaccine.2022.03.013"},{"issue":"9","key":"672_CR78","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1716677","volume":"379","author":"IM Blake","year":"2018","unstructured":"Blake IM, et al. Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine. N Engl J Med. 2018;379(9):834\u201345.","journal-title":"N Engl J Med"},{"issue":"5","key":"672_CR79","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1586\/14760584.2015.1001750","volume":"14","author":"M Patel","year":"2015","unstructured":"Patel M, et al. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14(5):749\u201362.","journal-title":"Expert Rev Vaccines"},{"issue":"36","key":"672_CR80","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1016\/j.vaccine.2017.04.036","volume":"35","author":"N Khetsuriani","year":"2017","unstructured":"Khetsuriani N, et al. Responding to a cVDPV1 outbreak in Ukraine: implications, challenges and opportunities. Vaccine. 2017;35(36):4769\u201376.","journal-title":"Vaccine"},{"issue":"1","key":"672_CR81","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12879-022-07397-0","volume":"22","author":"MA Al-Qassimi","year":"2022","unstructured":"Al-Qassimi MA, et al. Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020. BMC Infect Dis. 2022;22(1):414.","journal-title":"BMC Infect Dis"},{"issue":"33","key":"672_CR82","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.15585\/mmwr.mm7133e2","volume":"71","author":"R Link-Gelles","year":"2022","unstructured":"Link-Gelles R, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater - New York, June-August 2022. MMWR Morb Mortal Wkly Rep. 2022;71(33):1065\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"672_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1546","volume":"377","author":"J Wise","year":"2022","unstructured":"Wise J. Poliovirus is detected in sewage from north and east London. BMJ. 2022;377: o1546.","journal-title":"BMJ"},{"issue":"10354","key":"672_CR84","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0140-6736(22)01582-3","volume":"400","author":"M Hill","year":"2022","unstructured":"Hill M, Bandyopadhyay AS, Pollard AJ. Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use. Lancet. 2022;400(10354):713\u20135.","journal-title":"Lancet"},{"issue":"17","key":"672_CR85","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1128\/JVI.00370-06","volume":"80","author":"AJ Macadam","year":"2006","unstructured":"Macadam AJ, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol. 2006;80(17):8653\u201363.","journal-title":"J Virol"},{"issue":"5","key":"672_CR86","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","volume":"27","author":"MT Yeh","year":"2020","unstructured":"Yeh MT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27(5):736-751.e8.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"672_CR87","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41541-020-0176-7","volume":"5","author":"JL Konopka-Anstadt","year":"2020","unstructured":"Konopka-Anstadt JL, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5(1):26.","journal-title":"NPJ Vaccines"},{"issue":"1","key":"672_CR88","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41541-021-00355-y","volume":"6","author":"R Wahid","year":"2021","unstructured":"Wahid R, et al. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. NPJ Vaccines. 2021;6(1):94.","journal-title":"NPJ Vaccines"},{"issue":"10268","key":"672_CR89","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(20)32541-1","volume":"397","author":"I De Coster","year":"2021","unstructured":"De Coster I, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397(10268):39\u201350.","journal-title":"Lancet"},{"issue":"10268","key":"672_CR90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","volume":"397","author":"X Saez-Llorens","year":"2021","unstructured":"Saez-Llorens X, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397(10268):27\u201338.","journal-title":"Lancet"},{"issue":"1","key":"672_CR91","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41541-022-00437-5","volume":"7","author":"R Wahid","year":"2022","unstructured":"Wahid R, et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines. 2022;7(1):19.","journal-title":"NPJ Vaccines"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-022-00672-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-022-00672-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-022-00672-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T14:23:11Z","timestamp":1675261391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-022-00672-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1007\/s11357-022-00672-7","relation":{},"ISSN":["2509-2715","2509-2723"],"issn-type":[{"value":"2509-2715","type":"print"},{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"13 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}